日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A multi-stakeholder survey on communicating cost-effectiveness uncertainties to stakeholders: a case study of ICER

一项关于向利益相关者传达成本效益不确定性的多方利益相关者调查：以ICER为例

期刊:
影响因子:
doi:10.1093/haschl/qxag009
Versteeg, Jan-Willem; Goettsch, Wim G; Mantel-Teeuwisse, Aukje K; Ollendorf, Daniel; Leopold, Christine
发表日期：2026
文献求助 收藏

The effectiveness and value of brensocatib for the treatment of non-cystic fibrosis bronchiectasis

布伦索卡替治疗非囊性纤维化支气管扩张的有效性和价值

期刊:
影响因子:
doi:10.18553/jmcp.2026.32.3.392
McKenna, Avery; Wasfy, Jason H; Kim, Kibum; Touchette, Daniel R; Kim, Sodam; Richardson, Marina; Ollendorf, Daniel A
发表日期：2026
文献求助 收藏

Value attribution for oncology combination regimens: going beyond frameworks to balance innovation, access, and affordability

肿瘤联合治疗方案的价值归因：超越框架，平衡创新性、可及性和可负担性

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2025.1590944
Gaultney, Jennifer G; Ollendorf, Daniel; Sasane, Medha; Fernandez, Céline; Paranjpe, Krupa; Chen, Ting-Yen; Sandhu, Hera; Simoens, Steven
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Development of the natural history component of an early economic model for primary sclerosing cholangitis

早期原发性硬化性胆管炎经济模型自然史部分的构建

期刊:Orphanet Journal of Rare Diseases
影响因子:3.5
doi:10.1186/s13023-025-03658-8
Bowlus, Christopher; Levy, Cynthia; Kowdley, Kris V; Kachru, Nandita; Jeyakumar, Sushanth; Rodriguez-Guadarrama, Yael; Smith, Nathaniel; Briggs, Andrew; Sculpher, Mark; Ollendorf, Daniel
发表日期：2025
文献求助 收藏

The effectiveness and value of suzetrigine for moderate to severe acute pain: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council

舒泽三嗪治疗中重度急性疼痛的有效性和价值：临床与经济评价研究所中西部比较疗效公共咨询委员会的总结

期刊:
影响因子:
doi:10.18553/jmcp.2025.31.7.729
Nikitin, Dmitriy; Rind, David M; McQueen, Brett; Raymond, Finn; Sanchez, Sol; DiStefano, Michael J; Zemplenyi, Antal; Lee, Woojung; Ollendorf, Daniel
发表日期：2025
文献求助 收藏

Use of health technology assessments in specialty drug coverage decisions by US commercial health plans

美国商业健康计划在专科药物承保决策中使用健康技术评估

期刊:
影响因子:
doi:10.18553/jmcp.2025.31.3.289
Enright, Daniel E; van Duijnhoven, Emma G; Ollendorf, Daniel A; Chambers, James D
发表日期：2025
文献求助 收藏

How to make one line in the FDA Commissioner's new drug review program into a force for affordable access for patients

如何让FDA局长新药审查程序中的一条规定，成为确保患者能够负担得起药物的重要力量

期刊:
影响因子:
doi:10.1093/haschl/qxaf182
Emond, Sarah K; Ollendorf, Daniel A
发表日期：2025
文献求助 收藏

Modeling the Population Equity of Alzheimer Disease Treatments in the US

美国阿尔茨海默病治疗人群公平性建模

期刊:Jama Network Open
影响因子:9.7
doi:10.1001/jamanetworkopen.2024.42353
Synnott, Patricia G; Majda, Thomas; Lin, Pei-Jung; Ollendorf, Daniel A; Zhu, Yingying; Kowal, Stacey
阿尔茨海默症
发表日期：2024
文献求助 收藏

Designing collaborations involving health technology assessment: discussions and recommendations from the 2024 health technology assessment international global policy forum

围绕卫生技术评估的合作设计：2024年卫生技术评估国际全球政策论坛的讨论和建议

期刊:International Journal of Technology Assessment in Health Care
影响因子:3.1
doi:10.1017/S0266462324000436
Trowman, Rebecca; Migliore, Antonio; Ollendorf, Daniel A
发表日期：2024
文献求助 收藏

Lifecycle HTA: promising applications and a framework for implementation. An HTAi Global Policy Forum Task Force report

生命周期卫生技术评估：前景广阔的应用及实施框架。HTAi全球政策论坛工作组报告

期刊:International Journal of Technology Assessment in Health Care
影响因子:3.1
doi:10.1017/S0266462324000187
Pichler, Franz B; Boysen, Meindert; Mittmann, Nicole; Gilardino, Ramiro; Bruce, Andrew; Bond, Kenneth; Vreman, Rick A; Largeron, Nathalie; Banhazi, Judit; Ollendorf, Daniel A; Jain, Mohit; Upadhyaya, Sheela; Goettsch, Wim G
发表日期：2024
文献求助 收藏